Research programme: angiogenesis inhibitors - Allergan/Pharmacopeia

Drug Profile

Research programme: angiogenesis inhibitors - Allergan/Pharmacopeia

Alternative Names: PS388023; PS680648; PS780035

Latest Information Update: 06 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer Allergan; Ligand Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Benzimidazoles; Isoquinolines; Pyrimidines; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Eye-Disorders

Most Recent Events

  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 12 Jul 2005 This programme has been licensed to Allergan worldwide for the treatment of eye disorders
  • 21 Jun 2005 Preclinical trials in Eye disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top